Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 4/20 | 0.58 |
| ▸ | PGR | P06401 | 3/20 | 0.58 |
| ▸ | NR3C2 | P08235 | 2/20 | 0.58 |
| ▸ | CYP19A1 | P11511 | 14/20 | 0.56 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1656805 | 1.00 | AR (0.58) | ARPGRNR3C2CYP19A1SRD5A2 | |
| SCHEMBL7698849 | 0.81 | CYP19A1 (0.52) | CYP19A1 | |
| SCHEMBL13217275 | 0.81 | AR (0.57) | ARPGRNR3C2CYP19A1 | |
| SCHEMBL2929841 | 0.81 | AR (0.57) | ARPGRNR3C2CYP19A1 | |
| SCHEMBL8402139 | 0.81 | CYP19A1 (0.51) | CYP19A1 | |
| SCHEMBL12638972 | 0.80 | AR (0.56) | ARPGRNR3C2CYP19A1 | |
| SCHEMBL11809654 | 0.80 | PGR (0.64) | ARPGRNR3C2CYP19A1 | |
| SCHEMBL2832958 | 0.79 | SHBG (0.59) | ARPGRNR3C2CYP19A1SRD5A2 | |
| SCHEMBL8402137 | 0.79 | CYP19A1 (0.50) | CYP19A1 | |
| SCHEMBL7698847 | 0.79 | CYP19A1 (0.50) | CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150094291-A1 | Method and Substance for Improving the Emotional Development of an Infant | Opendot Research Co Limited (GB) | 2015-04-02 | — | — | US | disclosed |
| US-20150094291-A1 | Method and Substance for Improving the Emotional Development of an Infant | Opendot Research Co Limited (GB) | 2015-04-02 | — | — | US | disclosed |
| EP-2070941-A1 | Stereoselective synthesis of selective estrogen receptor down-regulators | Bayer Schering Pharma Aktiengesellschaft (DE) | 2009-06-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150094291-A1 | Method and Substance for Improving the Emotional Development of an Infant | BDNF, SNAP29, GAP43 | AR 4375/4885PGR 3277/4885NR3C2 582/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.